APA (7th ed.) Citation

LA, H., D, W., C, Y., L, B., GL, H., C, I., . . . HS, R. (2025). Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Annals of oncology : official journal of the European Society for Medical Oncology, 36(2), 172. https://doi.org/10.1016/j.annonc.2024.10.018

Chicago Style (17th ed.) Citation

LA, Huppert, et al. "Pathologic Complete Response (pCR) Rates for Patients with HR+/HER2- High-risk, Early-stage Breast Cancer (EBC) by Clinical and Molecular Features in the Phase II I-SPY2 Clinical Trial." Annals of Oncology : Official Journal of the European Society for Medical Oncology 36, no. 2 (2025): 172. https://doi.org/10.1016/j.annonc.2024.10.018.

MLA (9th ed.) Citation

LA, Huppert, et al. "Pathologic Complete Response (pCR) Rates for Patients with HR+/HER2- High-risk, Early-stage Breast Cancer (EBC) by Clinical and Molecular Features in the Phase II I-SPY2 Clinical Trial." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 36, no. 2, 2025, p. 172, https://doi.org/10.1016/j.annonc.2024.10.018.